GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR™ ELLIPTA™ for the treatment ...
GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse™ Ellipta® when added to Relvar®/Breo® Ellipta® in patients with COPD GlaxoSmithKline plc ...
(RTTNews) - Innoviva, Inc. (INVA) and GlaxoSmithKline plc (GSK, GSK.L) announced Thursday that the European Commission has approved a label update to Relvar Ellipta in patients with asthma. The label ...
Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ®. In addition, Innoviva retains a 15 percent economic ...
The European Commission approves new labeling for GlaxoSmithKline's (NYSE:GSK) Relvar Ellipta (fluticasone furoate/vilanterol) to include patients adequately controlled on both an inhaled ...
Submission supported by pivotal CAPTAIN study demonstrating statistically significant improvement in lung function compared with the ICS/LABA, Relvar/Breo Ellipta At least 30% of asthma patients ...
What: After word that a high-profile study fell short of its primary endpoint hit the tape yesterday, shares in Theravance crumbled by 21% today. So what: Theravance is the company behind ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback